Roche Holding AG
RHHBY
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
E: investor.relations@roche.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
103,249
Stocks News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
stocks
The 10 best global companies to invest in now
These undervalued stocks of high-quality companies are attractive investments today.
stocks
5 top US dividend shares from the best managers
These cheap dividend stocks are popular among highly rated concentrated fund managers.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,507.40 | 44.80 | 0.53% |
CAC 40 | 7,743.75 | 49.31 | 0.64% |
DAX 40 | 23,499.32 | 146.63 | 0.63% |
Dow JONES (US) | 41,249.38 | 119.07 | -0.29% |
FTSE 100 | 8,554.80 | 23.19 | 0.27% |
HKSE | 22,867.74 | 91.82 | 0.40% |
NASDAQ | 17,928.92 | 0.78 | 0.00% |
Nikkei 225 | 37,589.81 | 86.48 | 0.23% |
NZX 50 Index | 12,702.22 | 97.15 | 0.77% |
S&P 500 | 5,659.91 | 4.03 | -0.07% |
S&P/ASX 200 | 8,277.40 | 46.20 | 0.56% |
SSE Composite Index | 3,341.89 | 0.11 | -0.00% |